- Home
- FDMT vs ATAI Comparison
FDMT vs ATAI Comparison
Compare FDMT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- ATAI
- Stock Information
- Founded
- FDMT 2013
- ATAI 2018
- Country
- FDMT United States
- ATAI Germany
- Employees
- FDMT N/A
- ATAI N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- ATAI Health Care
- Exchange
- FDMT Nasdaq
- ATAI Nasdaq
- Market Cap
- FDMT 268.6M
- ATAI 280.2M
- IPO Year
- FDMT 2020
- ATAI 2021
- Fundamental
- Price
- FDMT $4.28
- ATAI $1.39
- Analyst Decision
- FDMT Buy
- ATAI Strong Buy
- Analyst Count
- FDMT 10
- ATAI 4
- Target Price
- FDMT $35.00
- ATAI $9.00
- AVG Volume (30 Days)
- FDMT 725.7K
- ATAI 3.3M
- Earning Date
- FDMT 05-08-2025
- ATAI 03-27-2025
- Dividend Yield
- FDMT N/A
- ATAI N/A
- EPS Growth
- FDMT N/A
- ATAI N/A
- EPS
- FDMT N/A
- ATAI N/A
- Revenue
- FDMT $37,000.00
- ATAI $331,000.00
- Revenue This Year
- FDMT $11,029.73
- ATAI $80.07
- Revenue Next Year
- FDMT $44.15
- ATAI N/A
- P/E Ratio
- FDMT N/A
- ATAI N/A
- Revenue Growth
- FDMT N/A
- ATAI N/A
- 52 Week Low
- FDMT $3.73
- ATAI $1.03
- 52 Week High
- FDMT $36.25
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- FDMT 43.33
- ATAI 37.03
- Support Level
- FDMT $3.73
- ATAI $1.32
- Resistance Level
- FDMT $4.40
- ATAI $1.50
- Average True Range (ATR)
- FDMT 0.35
- ATAI 0.15
- MACD
- FDMT 0.02
- ATAI -0.05
- Stochastic Oscillator
- FDMT 48.64
- ATAI 10.67
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.